At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,299 enrolled
Drug / intervention
TA-7284-Low +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating TA-7284-Low and TA-7284-High for Type 2 Diabetes Mellitus. Completed, enrolled 1,299 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedJul 2011
Primary CompletionNov 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJul 6, 2011
Enrollment StartMay 1, 2011
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.0 years ago
Interventions
TA-7284-Lowdrug
TA-7284-Low
TA-7284-Highdrug
TA-7284-High